Akero Therapeutics, Inc
Clinical trials sponsored by Akero Therapeutics, Inc, explained in plain language.
A public biopharmaceutical company developing treatments for metabolic diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug aims to halt liver scarring in 2,150 patients with fatty liver disease
Disease control Recruiting nowThis phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…
Phase 3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …
Phase 3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC